In SAS oral carcinoma cells, which are known for interleukin-6 signaling, YHO-1701 blocked multistep events accompanied by STAT3 dimerization, and also exhibited an enhanced antitumor effect with the multikinase inhibitor sorafenib8. This evidence concerns the gene STAT3 and lip and oral cavity carcinoma.